HHHelen P. Hazuda

Helen P. Hazuda

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Helen P. Hazuda has a total of 129 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Feasibility of Technology-Assisted Lifestyle Self-Monitoring in Older Adults With Type 2 Diabetes: Mixed Methods Pilot Study

    by Yan Du, Jing Wang, Byeong Yeob Choi, Helen P Hazuda, Lixin Song

    Background: Type 2 diabetes is a major public health concern in older adults. Healthy lifestyles, such as physical activity and healthy eating, are effective strategies for diabetes self-management. Increasing evidence shows that health technologies can promote healthy lifestyles for diabetes management. However, limited research has evaluated their use among older adults with type 2 diabetes. Objective: This study evaluated the feasibility and preliminary health outcomes of technology-assisted lifestyle monitoring for diabetes management in older adults with type 2 diabetes. The study also examined participants’ experiences to identify barriers and facilitators to sustained technology-assisted lifestyle modification. Methods: This 12-week pilot study used a pretest and posttest design. Feasibility was assessed by recruitment, retention, and adherence to device-based self-monitoring, including the percentage of days with tracked steps (PDWTs) and the percentage of days with food logs (PDWFLs). Fitbit fitness trackers paired with smartphone apps were used to track physical activity and food intake in 15 overweight/obese older adults with type 2 diabetes (mean age 70.5, SD 4.8 y). Self-monitoring behaviors were tracked throughout the study. Baseline and 12-week health outcomes (eg, hemoglobin A 1c [HbA 1c ] and physical function) were compared using paired 2-tailed t tests or Wilcoxon signed rank tests, as appropriate; effect sizes were calculated using Cohen d . Associations between self-monitoring data (PDWTs, average daily steps, PDWFL) and health outcomes were examined using Pearson or Spearman correlations. Semistructured interviews were conducted at the study completion, and thematic analysis was used to analyze qualitative data. Results: The target sample (n=15) was successfully enrolled over 6 months, with 100% retention at 12 weeks. Feasibility was supported by consistent use of wearable devices for self-monitoring of physical activity, although dietary logging adherence varied. HbA 1c decreased from baseline to 12 weeks (effect size −0.49, 95% CI –1.15 to –0.04; P =.04), and PDWFL was inversely correlated with HbA 1c ( r =−0.53; P =.04) at follow-up. The qualitative findings indicated that barriers and facilitators to technology-assisted lifestyle self-monitoring and diabetes management through lifestyle modifications exist across multiple levels, including the individual, interpersonal, organizational or community, and societal levels in older adults with type 2 diabetes. Factors at one level interacted with those at other levels. For example, limited technological proficiency challenged lifestyle tracking, while interpersonal and organizational support helped mitigate barriers. Conclusions: Technology-assisted self-monitoring of lifestyle behaviors was feasible in this sample of older adults with type 2 diabetes and was associated with favorable signals in glycemic control. While causal inferences cannot be drawn from this single-arm pilot study, observed within-subject changes and behavioral-clinical correlations support further evaluation of technology-assisted lifestyle self-monitoring. The findings also highlight the importance of addressing interconnected factors at multiple levels, tailored to older adults’ unique needs and capacities in diabetes self-management.


  • Open Access

    Supplemental Table S1 from Randomized Study of Metformin and Intensive Lifestyle Intervention on Cancer Incidence over 21 Years of Follow-up in the Diabetes Prevention Program

    by Brandy M. Heckman-Stoddard, Jill P. Crandall, Sharon L. Edelstein, Philip C. Prorok, Dana Dabelea, Richard Hamman, Helen P. Hazuda, Edward Horton, Mary A. Hoskin, Marjorie Perloff, et al.

    Supplemental Table S1 shows Cancer incidence by anatomical site.

  • Open Access

    DPPOS Investigators from Randomized Study of Metformin and Intensive Lifestyle Intervention on Cancer Incidence over 21 Years of Follow-up in the Diabetes Prevention Program

    by Brandy M. Heckman-Stoddard, Jill P. Crandall, Sharon L. Edelstein, Philip C. Prorok, Dana Dabelea, Richard Hamman, Helen P. Hazuda, Edward Horton, Mary A. Hoskin, Marjorie Perloff, et al.

    DPPOS Investigators: all investigators and staff that worked on DPP and DPPOS.

  • Open Access

    Supplemental Table S2 from Randomized Study of Metformin and Intensive Lifestyle Intervention on Cancer Incidence over 21 Years of Follow-up in the Diabetes Prevention Program

    by Brandy M. Heckman-Stoddard, Jill P. Crandall, Sharon L. Edelstein, Philip C. Prorok, Dana Dabelea, Richard Hamman, Helen P. Hazuda, Edward Horton, Mary A. Hoskin, Marjorie Perloff, et al.

    Supplemental Table S2 shows subgroup details for total cancer incidence.

  • Open Access

    Supplemental Table S4 from Randomized Study of Metformin and Intensive Lifestyle Intervention on Cancer Incidence over 21 Years of Follow-up in the Diabetes Prevention Program

    by Brandy M. Heckman-Stoddard, Jill P. Crandall, Sharon L. Edelstein, Philip C. Prorok, Dana Dabelea, Richard Hamman, Helen P. Hazuda, Edward Horton, Mary A. Hoskin, Marjorie Perloff, et al.

    Supplemental Table S4 shows adjusted effects of randomized and total metformin exposure on cancer incidence.

  • Open Access

    Supplemental Table S3 from Randomized Study of Metformin and Intensive Lifestyle Intervention on Cancer Incidence over 21 Years of Follow-up in the Diabetes Prevention Program

    by Brandy M. Heckman-Stoddard, Jill P. Crandall, Sharon L. Edelstein, Philip C. Prorok, Dana Dabelea, Richard Hamman, Helen P. Hazuda, Edward Horton, Mary A. Hoskin, Marjorie Perloff, et al.

    Supplemental Table S3 shows adjusted effects of metformin and lifestyle for total cancer.

  • Open Access

    Data from Randomized Study of Metformin and Intensive Lifestyle Intervention on Cancer Incidence over 21 Years of Follow-up in the Diabetes Prevention Program

    by Brandy M. Heckman-Stoddard, Jill P. Crandall, Sharon L. Edelstein, Philip C. Prorok, Dana Dabelea, Richard Hamman, Helen P. Hazuda, Edward Horton, Mary A. Hoskin, Marjorie Perloff, et al.

    Meta-analyses have reported a decrease in overall cancer incidence of approximately 10% to 40% with metformin use among individuals with diabetes. Lifestyle change could potentially reduce cancer incidence. The objective was to determine whether metformin or intensive lifestyle (ILS) intervention reduces the risk of cancer among adults at high risk of diabetes. The Diabetes Prevention Program (1996–2001) randomized 3,234 participants to ILS, metformin (850 mg twice daily), or blinded placebo. During follow-up through the Diabetes Prevention Program Outcomes Study, all participants were offered a modified lifestyle intervention, and metformin continued in an open-label metformin group. Participants reported cancer cases annually. Medical records were adjudicated for all reported events. The primary endpoint was total cancer incidence, comparing metformin versus placebo, with ILS versus placebo as a secondary objective. After a median follow-up of 21 years, 546 participants (173 metformin, 182 ILS, and 191 placebo) were diagnosed with a first incident cancer. Incidence rates of cancer were 9.8, 10.5, and 10.8 per 1,000 person-years in metformin, ILS, and placebo, respectively, with a HR of 0.90 (95% confidence interval, 0.73–1.10) for metformin compared with placebo and 0.96 (95% confidence interval, 0.79–1.18) for ILS compared with placebo. There were no differences between any treatment groups for obesity-related cancer or in sex-specific analyses. Neither assignment to metformin nor ILS reduced cancer incidence among adults at high risk of diabetes. These results may be impacted by increased nonstudy metformin usage over time due to the development of diabetes and reduced intensity of the ILS intervention over time.Prevention Relevance:This study examines both metformin and ILS intervention as primary cancer prevention interventions in people at high risk for type 2 diabetes.

  • Sociodemographic, Clinical, and Psychosocial Predictors of Short- and Long-term Study Retention in the Diabetes Prevention Program (DPP) Outcomes Study (DPPOS)

    by Ashley H Tjaden, Barbara H Braffett, Nicole M Butera, Maria Rosario Araneta, Owen Carmichael, Erik J Groessl, Helen P Hazuda, Mary A Hoskin, Uzoma Ibebuogu, Michelle F Magee, et al.

    OBJECTIVE: Success of longitudinal studies depends on retention of participants. We examined characteristics as predictors of retention among participants with prediabetes and type 2 diabetes (T2D) in the Diabetes Prevention Program (DPP) and the follow-up DPP Outcomes Study. RESEARCH DESIGN AND METHODS: A total of 3,234 adults at high risk of T2D joined the DPP (1996–1999, mean age 51 ± 10 years). They were randomized to lifestyle, metformin, or placebo intervention, and then followed through 2020. Logistic regression models estimated the association between baseline sociodemographic, clinical and psychosocial characteristics (life events, family functioning, social support), and short-term retention (∼3 years). Cox proportional hazards models, censoring at death, estimated the association between baseline and time-varying characteristics and time to dropout over the entire 20 years of follow-up. RESULTS: Among surviving participants (n = 3,218), 93% were retained after 3 years, and 75% of those surviving remained engaged over 20 years. Younger age was associated with dropout during DPP and over 20 years of follow-up. Female sex, non-White race and ethnicity, employment, and lack of baseline depressive symptoms were associated with better long-term retention. Over time, better health state (SF-36) (hazard ratio [HR]: 0.89 per 0.1 point; 95% CI: 0.83–0.95) was associated with retention. Greater BMI (HR: 1.06 per 5 kg/m2; 95% CI: 1.00–1.12), more recent life events (HR: 1.08; 95% CI: 1.02–1.14), and depressive symptoms (HR: 1.11 per 5 points; 95% CI: 1.05–1.18) were associated with reduced retention. Among adults 45–59 years of age at baseline, development of T2D was associated with better retention (HR: 0.75; 95% CI: 0.58–0.97). CONCLUSIONS: Twenty-year retention of a racially and geographically diverse cohort with prediabetes is possible. Retention was associated with age, psychosocial factors, T2D development, and BMI.


  • Randomized Study of Metformin and Intensive Lifestyle Intervention on Cancer Incidence over 21 Years of Follow-up in the Diabetes Prevention Program

    by Brandy M. Heckman-Stoddard, Jill P. Crandall, Sharon L. Edelstein, Philip C. Prorok, Dana Dabelea, Richard Hamman, Helen P. Hazuda, Edward Horton, Mary A. Hoskin, Marjorie Perloff, et al.

    Meta-analyses have reported a decrease in overall cancer incidence of approximately 10% to 40% with metformin use among individuals with diabetes. Lifestyle change could potentially reduce cancer incidence. The objective was to determine whether metformin or intensive lifestyle (ILS) intervention reduces the risk of cancer among adults at high risk of diabetes. The Diabetes Prevention Program (1996–2001) randomized 3,234 participants to ILS, metformin (850 mg twice daily), or blinded placebo. During follow-up through the Diabetes Prevention Program Outcomes Study, all participants were offered a modified lifestyle intervention, and metformin continued in an open-label metformin group. Participants reported cancer cases annually. Medical records were adjudicated for all reported events. The primary endpoint was total cancer incidence, comparing metformin versus placebo, with ILS versus placebo as a secondary objective. After a median follow-up of 21 years, 546 participants (173 metformin, 182 ILS, and 191 placebo) were diagnosed with a first incident cancer. Incidence rates of cancer were 9.8, 10.5, and 10.8 per 1,000 person-years in metformin, ILS, and placebo, respectively, with a HR of 0.90 (95% confidence interval, 0.73–1.10) for metformin compared with placebo and 0.96 (95% confidence interval, 0.79–1.18) for ILS compared with placebo. There were no differences between any treatment groups for obesity-related cancer or in sex-specific analyses. Neither assignment to metformin nor ILS reduced cancer incidence among adults at high risk of diabetes. These results may be impacted by increased nonstudy metformin usage over time due to the development of diabetes and reduced intensity of the ILS intervention over time. Prevention Relevance: This study examines both metformin and ILS intervention as primary cancer prevention interventions in people at high risk for type 2 diabetes.


  • Open Access

    Metformin use and stroke risk in Hispanic and non‐Hispanic veteran men with type 2 diabetes

    by Noor Imran, Eliana A Vasquez, Daniel MacCarthy, Mini Elizabeth Jacob, Sara Espinoza, Helen Hazuda, Sudha Seshadri, Claudia L. Satizabal, Chen‐Pin Wang

    Background: Stroke is a strong risk factor for dementia in the elderly. Traditional stroke risk factors such as hypertension and diabetes are also associated with the incidence and progression of dementia. There is a lack of data characterizing the effect of metformin use on stroke in racially/ethnically diverse cohorts. We sought to evaluate the impact of metformin as a preventative treatment in reducing the incidence of stroke risk in a cohort of older US veteran men with type 2 diabetes (T2D).Method: Our cohort included men with T2D, ≥65 years old, insulin/thiazolidinediones naïve, and without stroke history. Metformin use was defined as ≥180 days of prescription during 2002‐2003. Stroke incidence was identified by ICD9 codes 430‐438 (excluding TIA, 435) from inpatient/outpatient visits every year during 2004‐2012. Generalized estimating equations were used to estimate the odds ratios (OR) of stroke diagnosis over time associated with metformin use, where inverse propensity score weights (IPSW) for metformin use were incorporated to minimize confounding. Furthermore, the generalizability method was used to compare IPSW adjusted ORs between race/ethnicity groups after calibrating covariates between groups. Finally, inverse probability weights for survival were incorporated to project the adjusted ORs among the survivors.Result: Among 19,705 men with T2D, 81.3% were non‐Hispanic White, 5.3% Hispanic White, and 13.4% were non‐Hispanic Black. Overall, 26.7% used metformin (35.2% of Hispanic Whites, 27% of non‐Hispanic Whites, and 21.4% of non‐Hispanic Blacks). Metformin use was associated with attenuating the temporal increase in stroke risk during 2009‐2012 (vs. 2004‐2008) among Hispanic White (log(aOR) = ‐0.05, p‐value = 0.02), This stroke risk attenuation effect by metformin use was marginally different between Hispanic White with non‐Hispanic Black (p = 0.056) and significantly different between Hispanic White and non‐Hispanic White (p = 0.02). The stroke risk attenuation effect of metformin was not significant conditioned on survival.Conclusion: Our study suggests that metformin use is associated with a reduced distal stroke risk amongst men of Hispanic ethnicity compared to non‐Hispanics. Further studies are needed to elucidate the putative biological or pharmacological mechanism for this difference and to uncover the impact on dementia risk.